What if cancer cells could be re-engineered to turn against their own kind?
A new study in Science Translational Medicine, led by researchers at Brigham and Women’s Hospital, leverages the power of gene editing to take a critical step toward using cancer cells to kill cancer. The team reports promising results in preclinical models across multiple types of cancer cells, establishing a potential roadmap toward clinical translation for treating primary, recurrent and metastatic cancer.
“This is just the tip of the iceberg,” said corresponding author Khalid Shah MS, PhD, director of the Center for Stem Cell Therapeutics and Imaging (CSTI) in the BWH Department of Neurosurgery and faculty at Harvard Medical School and Harvard Stem Cell Institute (HSCI). “Cell-based therapies hold tremendous promise for delivering therapeutic agents to tumors and may provide treatment options where standard therapy has failed. With our technique, we show it is possible to reverse-engineer a patient’s own cancer cells and use them to treat cancer. We think this has many implications and could be applicable across all cancer cell types.”
The new approach capitalizes on cancer cells’ self-homing ability – the process in which cancer cells can track the cells of their kind that have spread within the same organ or to other parts of the body. Harnessing this power could overcome drug delivery challenges, helping get therapeutics to tumor sites that may otherwise be difficult to reach.
The team developed and tested two techniques to harness the power of cancer cells. The “off the shelf” technique used pre-engineered tumor cells that would need to be matched to a patient’s HLA phenotype (essentially, a person’s immune fingerprint). The “autologous” approach used CRISPR technology to edit the genome of a patient’s cancer cells and insert therapeutic molecules. These cells could then be transferred back into the patient.
To test both approaches, the team used mouse models of primary and recurrent brain cancer and breast cancer that has spread to the brain. The team saw direct migration of engineered cells to the sites of tumors and found evidence that the engineered cells specifically targeted and killed recurrent and metastatic cancer in the mice. The researchers report that the treatment increased the survival of the mice. Engineered cells were equipped with a “kill switch” that could be activated after treatment – PET imaging showed that this kill switch worked to eliminate the cells.
“Our study demonstrates the therapeutic potential of using engineered tumor cells and their self-homing properties for developing receptor-targeted therapeutics for various cancers,” said Shah.
Receive an email update when we add a new GENE EDITING article.
The Latest on: Engineered cancer cells
via Google News
The Latest on: Engineered cancer cells
- He Saved the Largest Venomous Snake in the Americas. Now, He Hopes It Could Save Human Lives. on December 6, 2018 at 10:34 am
However, if engineered properly, researchers have been able to isolate and repurpose certain toxins within venom to attack a specific target, including cancer cells. “When cancer goes metastatic ... […]
- Genetically Engineered Immune Cells May Help Fight Relapsed Blood Cancer on December 4, 2018 at 1:18 am
Genetically engineered immune cells offer new hope in the fight against relapsed blood cancer, reports a new study. The University of North Carolina Lineberger Comprehensive Cancer Center researchers ... […]
- Genetically engineered immune cells show promise for fighting relapsed blood cancer on December 3, 2018 at 9:09 pm
Researchers are presenting preliminary results from a clinical study of an investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin lymphoma expressing the CD30 protein marker. Univ... […]
- Early results show promise for using genetically engineered immune cells to fight relapsed blood cancer on December 3, 2018 at 12:34 pm
CHAPEL HILL – University of North Carolina Lineberger Comprehensive Cancer Center researchers reported promising early results from a clinical study of an investigational cellular immunotherapy that u... […]
- Swift gene-editing method may revolutionize treatments for cancer, infectious diseases on November 22, 2018 at 9:22 pm
In the new study, Marson and his colleagues engineered T-cells to recognize human melanoma cells. In mice carrying the human cancer cells, the modified T-cells went right to the cancer, attacking it. ... […]
- Researchers have unlocked secrets about engineered protein receptor, CAR on November 7, 2018 at 9:09 am
However, cancer cells can mask themselves, making it harder for the good cells, such as T cells, to kill them. With CAR T cell therapy, a person's T cells are removed, genetically engineered with prot... […]
- New immunotherapy technique can specifically target tumor cells, study reports on November 6, 2018 at 1:03 pm
Zhao added that traditional cancer treatments have offered a one-size-fits-all disease response, such as chemotherapy drugs which can involve systemic and serious side effects. T cell receptor (TCR)-e... […]
- Engineered Cymerus™ MSCs Demonstrate Anti-Cancer Effects in Preclinical Studies on October 18, 2018 at 11:00 am
The effects of these engineered Cymerus MSCs on the viability of both human melanoma (skin cancer) and human glioblastoma (brain cancer) cells were evaluated in in vitro test systems and the therapeut... […]
- Engineered natural killer cells may be the next great cancer immunotherapy on September 13, 2018 at 10:20 am
The cancer fighters known as CAR T cells have proved their prowess in recent years. Three therapies using the altered T cells against lymphoma or leukemia have won U.S. Food and Drug Administration ap... […]
via Bing News